Results 111 to 120 of about 2,387 (195)

Effects of Nirsevimab Introduction on Bronchiolitis and Respiratory Syncytial Virus in Catalonia

The respiratory syncytial virus (RSV) causes 70% of bronchiolitis cases and thousands of annual deaths, particularly in the paediatric population under six months, placing a significant burden on the public health system.
Valette Hohn, Berta
core   +1 more source

The Utilization of a Reference Guide to Promote Nurse Confidence in Providing Parental Education About Nirsevimab Vaccine

In July 2023, the FDA approved Nirsevimab (Beyfortus), a monoclonal antibody that provides direct protection to infants against respiratory syncytial virus (RSV), a dangerous respiratory virus that is the leading cause of infant hospitalization in the ...
Drabek, Allison A, Nowak, Julia, Kalasky, Audrey, Killich, Taylor   +3 more
core   +1 more source

How a major discovery can become a public health failure when used subotptimally: lessons from early nirsevimab implementation

Italian Journal of Pediatrics
Background In this Debate, based on our clinical data from the “pre-nirsevimab” and “first year of nirsevimab implementation” bronchiolitis seasons, we challenge the validity of policy decisions that led to partial immunization coverage of eligible ...
Danilo Buonsenso, Aida Perramon-Malavez, Rosa Morello, Carolina Gentili, Marta Bellorofonte, Antoni Soriano-Arandes   +5 more
doaj   +1 more source

Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations

Importance: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants and young children, imposing a substantial burden on health care systems.
Caselli D., Alberti I., Bertolucci G., Zago A., Milani G. P., Piccotti E., Lanari M., Indolfi G., Savoia F., Giannattasio A., Frusciante A., Notarangelo L. D., Felici E., Attanasi M., Silvestro E., Garazzino S., Manzini A., Pellegrino R., Attaianese F., Soro F., Mandato C., Ricci S., Nunziata F., Casotto V., Bressan S., Moriondo M., Trapani S., Martelli G., Iudica G., Azzari C., Chiarelli F., Cazzato S., Galeone M. A., Gitto E., Peroni D., Guida F., Sisto A., Arico M., Guerriero A., Ponticiello E., Rulli I., Carreras G., Tonetto S., Dani C.   +43 more
core   +1 more source

Nirsevimab: a promising therapy for RSV

The Lancet Microbe, 2022
openaire   +1 more source

Mutational constraints on RSV F and its neutralization by antibodies. [PDF]

Nature
Simonich CAL, McMahon TE, Juviler G, Kampman L, Chu HY, Bloom JD.   +5 more
europepmc   +1 more source

Nirsevimab for respiratory syncytial virus prevention: A comprehensive product review. [PDF]

Hum Vaccin Immunother
Razzini JL, Martinon-Torres F.
europepmc   +1 more source

Reply to Hodges et al. Comment on "Kura et al. Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. <i>Vaccines</i> 2026, <i>14</i>, 411". [PDF]

Vaccines (Basel)
Kura K, Lang JC, Wang D, Choi Y, Goveia MG, Sinha A, Chen YH, Elbasha EH.   +7 more
europepmc   +1 more source

First- and Second-Year Outcomes After Nirsevimab Immunization

Importance The consistency of nirsevimab effectiveness across consecutive seasons and its broader clinical protective effects remain to be fully characterized.
Epiphane Kolla, Amélie Gabet, Ludovic Tréluyer, Marie-Joelle Jabagi, Antoine Rachas, Marion Bertrand, Valérie Olié, Mahmoud Zureik, Olivia Weill   +8 more
core   +1 more source

Impact du nirsevimab sur les hospitalisations pour bronchiolites à VRS au CHU de Clermont-Ferrand durant l'hiver 2023-2024

Contexte : le virus respiratoire syncytial (VRS) est la cause la plus fréquente de bronchiolite chez les nourrissons pouvant causer des atteintes graves allant jusqu’au décès.
Couteau, Lorène
core   +1 more source